Latest currency news


Roche net income up 9% in Q2

Net profit of Roche Holding AG in April-June amounted to 8.53 billion Swiss francs ($8.78 billion) compared to 7.8 billion Swiss francs in the same period last year. the figure increased by 9%. Operating profit rose to 11.54 billion francs from 10.08 billion francs, according to a press release from the Swiss pharmaceutical company.

Revenue increased by 5.1% to 32.29 billion francs from 30.71 billion francs. The consensus forecast of analysts polled by the company itself suggested revenue growth to 31.95 billion francs.

Sales of the pharmaceutical division of Roche in the last quarter increased by 3%, to 22.35 billion francs.

The diagnostic division increased revenue by 11% to 9.95 billion francs from 9.04 billion francs.

Roche reaffirmed its guidance for 2022, according to which the company expects revenue growth of 1-3% (low-single digits) excluding changes in exchange rates. The forecast for earnings growth per share is 3-6% (low- to mid-single digit) excluding changes in exchange rates.

Roche is one of the world’s leading companies in pharmaceuticals and diagnostics, and is a major manufacturer of biotech medicines for the treatment of cancer, ophthalmic and autoimmune diseases, severe viral infections and disorders of the central nervous system.

Roche shares shed 0.4% in trading in Zurich on Thursday. Over the past 12 months, the company’s capitalization has decreased by 4.7%.


About author

Oxford graduate with honors. He worked in large financial projects for well-known Wall Street corporations. After he earned his first capital and a reputation as a successful trader, he opened his own company. At the moment, the growth of the company's capital is 20% per year.
Related posts

Japan from August 1 introduces a ban on the import of gold from the Russian Federation


European stock markets decline moderately during trading


Business confidence in German economy Ifo declined in July


NLMK Group reduced steel production by 1% over the first half of the year

Sign up for our Newsletter and
stay informed

Leave a Reply

Your email address will not be published.